Takeda Pharmaceutical Limited

3 days ago · seekingalpha.com

Takeda Pharmaceutical is reiterated as a Hold, with concerns about its ability to replace major drug revenues and current valuation. Operating margin improved to 17% due to lower amortization, but operating cash flow declined to $2.74B, highlighting weak underlying cash generation. New products like Mimrylo and Orzeyful are slow to ramp and currently contribute minimally, while Entyvio remains the key revenue driver.

3 days ago · marketbeat.com

Takeda Pharmaceutical NYSE: TAK reported first-half fiscal 2026 results that management said were in line with expectations as the company invested in new product launches and its late-stage pipeline while using savings from a transformation program to support profitability.

3 days ago · benzinga.com

Takeda Pharmaceutical Co Ltd (NYSE:TAK) on Thursday reported second-quarter adjusted earnings of 48 cents per share, beating the consensus of 31 cents.

3 days ago · seekingalpha.com

Takeda Pharmaceutical Company Limited (TAK) Q2 2026 Earnings Call Transcript

4 days ago · businesswire.com

OSAKA, Japan--(BUSINESS WIRE)--Takeda (TOKYO:4502/NYSE:TAK) announced financial results for the first half of fiscal year 2026 (April 1, 2026, to Sept. 30, 2026). The period included the approval of ORZEYFUL (oveporexton) in the U.S., Japan and China, the U.S. launch of MIMRYLO (rusfertide), progress in the regulatory review of zasocitinib, and additional clinical evidence across the late-stage pipeline. Takeda's focus remains on execution against the first horizon of its growth strategy: succe.

10 days ago · businesswire.com

OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda (TSE:4502/NYSE:TAK) announced positive results from the Phase 3 G-HOPE-001 study (NCT06238843) of arcotatug tavatecan (TAK-921; Innovent R&D code: IBI343) in patients with Claudin (CLDN)18.2-positive, previously treated, advanced gastric or gastroesophageal junction adenocarcinoma (G/GEJA). Results from two prespecified interim analyses, which were shared in a late-breaking oral presentation at the 2026 European Society for Medical On.

14 days ago · businesswire.com

OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda (TSE:4502/NYSE:TAK) announced new data from VERDICT (NCT04259138), showing that treating adults with intravenous ENTYVIO® (vedolizumab) to achieve corticosteroid-free (CSF) disease clearance versus CSF symptomatic remission alone, resulted in a significantly longer time to first ulcerative colitis (UC)-related complication (hazard ratio 0.33 [95% confidence interval 0.17-0.67]; P=0.0014), reducing UC complication risk by nearly 70 percent.

19 days ago · businesswire.com

OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda (TSE:4502/NYSE:TAK) announced today that ORZEYFUL (oveporexton) is now available in Japan and China for the treatment of narcolepsy type 1 (NT1), providing first access to clinicians to prescribe treatment with the new class of medicine. ORZEYFUL is a first-in-class orexin receptor 2 (OX2R) agonist, in tablet form, designed to treat the underlying orexin deficiency associated with NT1. “We're excited at the potential to fundamentally chan.

20 days ago · seekingalpha.com

Takeda gets its prior buy rating reaffirmed. Positive factors are recent drug approval, robust future pipeline, global reach, and an investment-grade rating. TAK serves several clinical areas, filling specific medical needs.

1 month ago · reuters.com

Roche on Wednesday ​said it ‌was proposing Christoph Weber, the ​former ​CEO of Takeda Pharmaceuticals , ⁠for election ​to the ​Swiss company's board of directors at ​its AGM ​next March.